Pfizer Inc has said the final analysis of its antiviral COVID-19 pill showed close to 90 percent efficacy in preventing hospitalisations and deaths in high-risk patients with recent lab data suggesting the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus.The US drugmaker’s remarks came on Tuesday after it said last month the oral medicine was about 89 percent effective in preventing hospitalisations or deaths when compared with placebo based on interim results in about 1,200 people.The data disclosed on Tuesday includes an additional 1,000 people.
Load More
Load More